...
首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >Novel self-assembled core-shell nanoparticles based on crystalline amorphous moieties of aliphatic copolyesters for efficient controlled drug release
【24h】

Novel self-assembled core-shell nanoparticles based on crystalline amorphous moieties of aliphatic copolyesters for efficient controlled drug release

机译:基于脂族共聚酯结晶无定形部分的新型自组装核-壳纳米粒子,可有效控制药物释放

获取原文
获取原文并翻译 | 示例
           

摘要

Poly(propylene succinate-co-caprolactone) copolymers [P(PSu-co-CL)] with different epsilon-caprolactone (epsilon-CL) to propylene succcinate (PSu) monomer ratios were synthesized using ring opening polymerization. These polymers consisted of crystalline poly(epsilon-caprolactone) (PCL) and amorphous poly(propylene succinate) (PPSu) moieties, as shown by WAXD. In vitro biocompatibility studies showed that these copolyesters are biocompatible. Drug-loaded nanoparticles, using tibolone as a model drug, were prepared by the solvent evaporation method. Nanoparticle size ranged between 150 and 190 nm and decreased with increasing propylene succinate (PSu) ratio in the copolymers. Nanoparticle yield, encapsulation efficiency, and drug loading increased with increasing PSu ratio. Scanning Electron Microscopy (SEM) revealed that the prepared nanoparticles had a spherical shape and Transmission Electron Microscopy (TEM) showed that they were self-assembled in core-shell structures. Amorphous PPSu and crystalline PCL comprised the core and shell, respectively. The drug is mainly located into the amorphous core in the form of nanocrystals. Drug release studies showed that complete release of the drug from the nanoparticles occurs over a period of 50 h. The release rate is greatly influenced by the copolymer composition, nanoparticle size, and encapsulation efficiency. Among the main advantages of the nanoparticles produced in this study is the absence of burst effect during drug release.
机译:使用开环聚合反应合成具有不同ε-己内酯(epsilon-CL)与琥珀酸丙二酯(PSu)单体比例的聚(琥珀酸丙二醇酯-共-己内酯)共聚物[P(PSu-co-CL)]。这些聚合物由结晶聚(ε-己内酯)(PCL)和非晶聚(琥珀酸丙二酯)(PPSu)部分组成,如WAXD所示。体外生物相容性研究表明,这些共聚酯具有生物相容性。以替勃龙为模型药物,通过溶剂蒸发法制备了载药纳米颗粒。纳米颗粒的大小在150到190 nm之间,并且随着共聚物中琥珀酸丙二酯(PSu)比的增加而减小。纳米粒子的产量,包封效率和载药量随PSu比的增加而增加。扫描电子显微镜(SEM)显示所制备的纳米颗粒具有球形形状,并且透射电子显微镜(TEM)显示它们是自组装的核-壳结构。非晶态的PPSu和结晶态的PCL分别由核和壳组成。该药物主要以纳米晶体的形式位于非晶核中。药物释放研究表明,药物从纳米颗粒中完全释放会在50小时内发生。释放速率受共聚物组成,纳米颗粒尺寸和包封效率的影响很大。在这项研究中产生的纳米颗粒的主要优点之一是在药物释放过程中没有爆发效应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号